Frontlight ResearchEarly access
Taking people in PolandPhase 2/3
Tests etanercept against placebo in adults with SAPHO syndrome
Tests etanercept against placebo in adults with SAPHO syndrome, a rare joint and skin disease.
Key facts
- Who runs it
- Narodowy Instytut Geriatrii Reumatologii I Rehabilitacji Im Prof. Dr Hab. Med. Eleonory Reicher
- Where
- Olsztyn, Szczecin, and Warsaw, PolandSee the 3 sites
- Registry title
- Study of the efficacy and safety of etanercept treatment in patients with SAPHO syndrome
- Status
- Recruiting
- Phase
- Phase 2/3
- People taking part
- 60 people, planned
- Started
- 22 Oct 2024
- Expected to end
- 31 Jul 2028
- Type of study
- Interventional
- Record updated
- 20 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with SAPHO syndrome who still have active disease and pain while taking standard treatment. It compares etanercept with placebo.
- Age
- Over 18 years
- Sex
- Men and women can join.
- Disease stage
- SAPHO syndrome diagnosed by the modified Kahn criteria from 2003. Overall disease and pain must both score 4 cm (1.6 in) or more on the VAS scale.
- Earlier treatment
- No change in NSAID dose in the last 4 weeks. No change in DMARD dose in the last 12 weeks. No biological or targeted synthetic drugs in the last 12 weeks. No corticosteroids (by mouth or local injection) in the last 4 weeks.
Main reasons for not taking part
- Pregnancy or breastfeeding
- Cannot use effective contraception during the study
- Conditions listed in the Enbrel product information (SmPC)
- Any medical condition that the investigator judges to rule out etanercept treatment
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Diagnosis of SAPHO syndrome according to modified Kahn criteria from 2003
- Age over 18
- Patient overall disease and pain assessment on VAS both ≥ 4 cm
- Expressing informed consent to participate in the study
Who cannot take part
- Use of biological drugs / synthetic targeted drugs in the last 12 weeks
- Use of corticosteroids (orally or local injections) in the last 4 weeks
- Dose modification of disease-modifying antirheumatic drugs (DMARDs) over the past 12 weeks
- Any medical condition that the investigator judges to contraindicate etanercept treatment
- According to the Summary of Product Characteristics (SmPC) for Enbrel
- Pregnancy, breastfeeding, inability to use effective contraception during the examination
- Change in the dose of NSAIDs treatment in the last 4 weeks
Where in Poland
- University of Warmia and MazuryOlsztyn, PolandTaking people
- Pomeranian Medical UniversitySzczecin, PolandTaking people
- Narodowy Instytut Geriatrii Reumatologii I Rehabilitacji Im Prof. Dr Hab. Med. Eleonory ReicherWarsaw, PolandTaking people
About the trial
What the trial wants to find out
The aim of the proposed clinical trial is to evaluate the efficacy and safety of etanercept therapy compared to placebo in patients with SAPHO syndrome who continue to receive standard treatment with NSAIDs and / or conventional disease-modifying antirheumatic drugs.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- A multicenter, randomized, double-blind clinical trial evaluating the efficacy and safety of etanercept versus placebo in the treatment of patients with SAPHO syndrome
- Plain-language title
- Tests etanercept against placebo in adults with SAPHO syndromeGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 20 April 2026